Mid-term (up to 12 years) clinical and echocardiographic outcomes of percutaneous transvenous mitral commissurotomy in patients with rheumatic mitral stenosis

Yahya Dadjo2, Maryam Moshkani Farahani2, Reza Nowshad1,2, Mohsen Sadeghi Ghahrodi2, Alireza Moaref3 and Javad Kojuri1*

Abstract

**Background:** Rheumatic heart disease (RHD) is still a concerning issue in developing countries. Among delayed RHD presentations, rheumatic mitral valve stenosis (MS) remains a prevalent finding. Percutaneous transvenous mitral commissurotomy (PTMC) is the intervention of choice for severe mitral stenosis (MS). We aimed to assess the mid-term outcome of PTMC in patients with immediate success.

**Methods:** In this retrospective cohort study, out of 220 patients who had undergone successful PTMC between 2006 and 2018, the clinical course of 186 patients could be successfully followed. Cardiac-related death, undergoing a second PTMC or mitral valve replacement (MVR) were considered adverse cardiac events for the purpose of this study. In order to find significant factors related to adverse cardiac outcomes, peri-procedural data for the studied patients were collected. The patients were also contacted to find out their current clinical status and whether they had continued secondary antibiotic prophylaxis regimen or not. Those who had not suffered from the adverse cardiac events were additionally asked to undergo echocardiographic imaging, in order to assess the prevalence of mitral valve restenosis, defined as mitral valve area (MVA) < 1.5 cm² and loss of ≥ 50% of initial area gain.

**Results:** During the mean follow-up time of 5.69 ± 3.24 years, 31 patients (16.6% of patients) had suffered from adverse cardiac events. Atrial fibrillation rhythm (p = 0.003, HR = 3.659), Wilkins echocardiographic score > 8 (p = 0.028, HR = 2.320) and higher pre-procedural systolic pulmonary arterial pressure (p = 0.021, HR = 1.031) were three independent predictors of adverse events and immediate post-PTMC mitral valve area (IMVA) ≥ 2 cm² (p < 0.001, HR = 0.06) was the significant predictor of event-free outcome. Additionally, follow-up echocardiographic imaging detected mitral restenosis in 44 patients (23.6% of all patients). The only statistically significant protective factor against restenosis was again IMVA ≥ 2 cm² (p = 0.001, OR = 0.240).

*Correspondence: Kojuri@yahoo.com
1 Cardiology Department, Clinical Research Center, Namazi Hospital, Shiraz University of Medical Sciences, Zand St, Cardiology Office, Shiraz, Iran
Full list of author information is available at the end of the article
Introduction
Rheumatic heart disease (RHD), despite the decrease in its prevalence in some parts of the world, continues to be a major medical concern in developing countries [1, 2]. Among delayed RHD presentations, rheumatic mitral valve stenosis remains a common finding. It accounts for the great majority of all cases of mitral stenosis (MS) even in developed nations [3, 4]. Since the early 1980s with the introduction of the Inoue balloon, the management of MS has changed considerably, and percutaneous transvenous mitral commissurotomy (PTMC) has become the mainstay of treatment for symptomatic patients with severe MS and favorable valve anatomy [5, 6].

Although the immediate success rate of PTMC is relatively the same as that of surgical commissurotomy techniques, the long-term results and appropriate patient selection for this procedure remain debatable [7, 8]. Regarding morphological features, several echocardiographic criteria have been developed, with the semi-quantitative Wilkins score being the most widely used [9, 10]. Nonetheless, several randomized trials have shown that other characteristics may be just as important in predicting the incidence of adverse clinical events in the long-term [11–18]. But because of differences among trials in study design, the criteria and techniques used, and the duration of follow-up, the success rate and the reported predictive factors have not been always similar. The same issues surround the study of mitral valve restenosis, which is expected at some point in the course of follow-up due to the persistence of underlying rheumatic pathology. But again, the timing of appearance and incidence rates have been shown to be multifactorial [19, 20].

Because only one valid study, to the best of our knowledge, is available in our country (Iran) on the late results of PTMC [16], the present study was designed to determine the mid-term outcome of PTMC at local tertiary centers, and to identify which characteristics are potentially helpful in predicting adverse cardiac events as well as mitral valve restenosis. We also investigated whether a continuing secondary antibiotic prophylaxis regimen had any positive effects on the long-term outcome in these patients.

Material and methods
Study population and design
This research was designed as single-technique (Inoue balloon), multicenter retrospective cohort study. The target group of this study consisted of 220 patients with symptomatic rheumatic MS who had undergone PTMC at 4 hospitals with similar procedural setups and registry systems (Baqiyatallah, Namazi, Shahid-Faghihi and Kowsar) under the supervision of Baqiyatallah and Shiraz Universities of Medical Sciences between April 2006 and January 2018.

The inclusion criteria for the participants were: (1) age more than 20 years at the time of PTMC; (2) immediate post-PTMC mitral valve area (IMVA), obtained through the first session of echocardiography during the first day after PTMC, $\geq 1.5 \text{ cm}^2$, or for lower values, at least 50% increase in pre-PTMC mitral valve area (MVA); 3) an initial cardiovascular event-free period of at least 6 months after the procedure.

The exclusion criteria consisted of: (1) more than 2+ mitral regurgitation (MR) immediately after the procedure; (2) immediate cardiovascular event during the hospital stay after the procedure; (3) more than mild aortic stenosis or sufficiency before PTMC; (4) history of previous PTMC or surgical mitral procedures.

The study design and steps were approved by the ethics committees at both Baqiyatallah and Shiraz Universities of Medical Sciences.

PTMC technique
All PTMC procedures were done with an Inoue balloon catheter via anterograde trans-septal approach in all patients. Right and left cardiac catheterization was performed before and during the procedure to assess hemodynamic changes. Optimal balloon size (in millimeters) was estimated with the height (cm)/10 + 10 formula. The balloon was inflated in a step-wise fashion from lower to higher volumes. After each inflation, changes in trans-mitral mean pressure gradient (TMPG) and the degree of mitral regurgitation (MR) were monitored. Based on interventionist’s judgement and in order to achieve optimal results, balloon inflation could be continued up to 1–2 mm more than the estimated size. In the last stage,
left ventriculography was conducted to assess the degree of final MR.

**Echocardiography**
All of the studied patients, for whom rheumatic MS had been previously by echocardiography confirmed, underwent transthoracic Doppler echocardiography (TTE) in the week before PTMC. MVA was measured by planimetry in the short axis view, and also by pressure half-time quantification when atrial fibrillation (AF) or MR were not serious enough to interfere with its interpretation. The degree of MR was reported on a semi-quantitative scale of 0 to 4 based on Doppler color flow mapping. Mitral valve morphology was also evaluated with the standard Wilkins echocardiographic scoring system. Pulmonary arterial pressure was estimated by measuring systolic pulmonary arterial pressure (sPAP) in mmHg based on the trans-tricuspid regurgitation jet. Other significant variables in this study were left atrial diameter in centimeters, and mean trans-mitral pressure gradient (TMPG) in mmHg.

Each patient also had one session of transesophageal echocardiography during the day before the procedure in order to rule out thrombi in the left atrium or the left atrial appendage. Another session of TTE was performed during the first day after the procedure to confirm the immediate success of PTMC, also to obtain immediate post-PTMC values and at last to rule out acute complications such as severe MR or cardiac tamponade.

**Follow-up**
The clinical condition of the patients was recorded as their New York Heart Association (NYHA) functional class before the procedure. Their clinical status was also followed in their inpatient and also outpatient records, as there had been an annually planned clinical visit and TTE evaluation for the studied patients, in all of our centers. For the purpose of this study, the patients or their first-degree relatives were again contacted by telephone in order to record the occurrence and exact timing of any adverse cardiac events, and also to reassess their current NYHA functional class status. Adverse cardiac events considered significant for the purpose of this study included: (1) cardiac-related death, (2) another session of PTMC, or (3) surgical procedure of mitral valve replacement (MVR). The participants were also questioned whether they had continued secondary antibiotic prophylaxis regimen or not. Only standard regimens of intramuscular injection of 1.2 million units of penicillin G benzathine every 4 weeks, or in case of allergy to penicillin, usage of azithromycin (250 mg orally once daily) or erythromycin (250 mg twice daily) were considered valid in this study. Furthermore, Patients who had been event-free until that time were asked to undergo another TTE evaluation after providing their informed consent.

**Statistical analysis**
Continuous variables are reported as the mean ± SD. Categorical and nominal variables are shown as the number and percentage, and were pooled in some cases in order to facilitate the interpretation of the results. Initially, univariable Cox proportional hazards regression analysis was used to assess the relationship between variables and adverse cardiac events at follow-up. In the next stage, Cox multivariable regression was also performed to single out the independent variables. To evaluate the variables for the occurrence of restenosis during follow-up, uni- and multivariable logistic regression analysis was used. In order to enter independent variables into the multivariable analyses, certain p value cut-offs based on univariable analysis results were implemented at each stage. Receiver operating characteristic (ROC) curves were generated to determine the best cut-off point for IMVA in interpreting the results. An additional analysis was performed with the help of paired sample t-test and Wilcoxon signed-rank test to evaluate the differences in the characteristics of the Event-free patients between the beginning point of the study and the time of last echocardiographic and clinical follow-up. For all analyses a p value of 0.05 or less was considered statistically significant. All data analyses were done with IBM SPSS Statistics version 23 software.

**Patient and public involvement statement**
This research was based on active registry of patients with mitral stenosis, all patients were asked to freely report their comments and problems during follow up and all tests specifically needed for research including visits, laboratory and echocardiographic studies were done free of charge for all patients.

Patients were completely informed about aims, scopes and methods of research before and during conduction, but they had no active role in design or dissemination of results.

The results of all evaluations were reported to patients and they were referred to subspecialist for proper managements, whenever it was needed (Additional file 1).

**Results**
It is worthy of note that aside from 220 cases included in this study, based on our database, the rate of early complications in our centers was around 6% (14 patients). The causes included occurrence of cardiac tamponade, immediate severe MR or rupture of left atrium during the procedure (prompting urgent surgical intervention) as well as PTMC failure mainly due to failed puncture.
of interatrial septum, failed attempt or limited success in ballooning the mitral valve, for which another session of intervention or surgery was needed in the following few weeks or months.

**Clinical follow-up**

Out of 220 patients who met the inclusion criteria, the clinical course of 186 patients could be successfully followed. Mean follow-up time was 5.69 ± 3.24 years. Their primary characteristics are summarized in Table 1. Of the remaining patients, 12 were lost in follow-up: 3 had died of non-cardiac causes, and for 19 patients the required follow-up data could not be obtained in full (Fig. 1).

Out of a total of 186 patients, 31 (16.6%) suffered from one of adverse cardiac events during the follow-up period. The frequency of each cardiac event was: second PTMC session, 5 (2.6%); MVR, 22 (11.8%); and cardiac-related death, 4 (2.1%). The mean interval between PTMC and events was 4.67 ± 2.43 years. The remaining 155 patients (83.3%) were considered the event-free. (Table 1).

In the next step, demographic, clinical and echocardiographic characteristics were compared between the event-positive and event-free groups. Univariable analysis was done with a univariable Cox proportional hazards model. This analysis showed that AF cardiac rhythm (p < 0.001), lower IMVA (p < 0.001), higher degree of immediate MR (p = 0.002), Wilkins score > 8 (p = 0.021), higher baseline sPAP (p = 0.003), and lack of continuing secondary penicillin prophylaxis (p = 0.03) had a statistically significant association with incidence of adverse cardiac events. The results of this analysis are shown in Table 2.

Then, multivariable Cox regression analysis was applied for the variables with p value < 0.05 in the univariable analysis in order to identify which variables from the previous stage remained significant. This analysis disclosed that only AF rhythm (p = 0.003), IMVA < 2 cm² (p < 0.001), high pre-PTMC sPAP (p = 0.021), and Wilkins echocardiographic score > 8 (p = 0.028) were the independent variables that were predictive of adverse cardiac events. The results of the multivariable analysis are summarized in Table 3.

**Restenosis at follow-up**

In the next step, we investigated the echocardiographic findings in the event-free group of patients in order to assess mitral restenosis rate. The mean follow-up time for this group was 5.89 ± 3.36 years. Restenosis was defined as loss of more than 50% of the initial increase in MVA and simultaneously MVA < 1.5. Of 155 event-free patients, 44 (23.6% of all patients) were found to

---

**Table 1** Primary characteristics of the patients

| Characteristics                          | All patients | Event-free group | Event-positive group | p value |
|------------------------------------------|--------------|------------------|----------------------|---------|
| **Number**                               | 186          | 155              | 31                   |         |
| **Demographic**                          |              |                  |                      |         |
| Age (in years)                           | 46.97 ± 11.67| 46.43 ± 11.54    | 49.65 ± 12.15        | 0.08    |
| Female sex                               | 152 (81.7%)  | 125 (80.6%)      | 27 (87%)             | 0.19    |
| **Clinical**                             |              |                  |                      |         |
| NYHA functional class > 2               | 142 (76.3%)  | 120 (77.4%)      | 22 (70.9%)           | 0.57    |
| AF cardiac rhythm                        | 48 (25.8%)   | 32 (20.6%)       | 16 (51.6%)           | < 0.001 |
| Antibiotic (penicillin) prophylaxis      | 61 (32.7%)   | 55 (35.4%)       | 6 (19.3%)            | 0.03    |
| **Echocardiographic (Pre-PTMC)**         |              |                  |                      |         |
| E.F (%)                                  | 55.60 ± 4.45 | 55.69 ± 4.21     | 55.16 ± 5.55         | 0.11    |
| Left atrial diameter(cm)                | 4.48 ± 0.58  | 4.46 ± 0.61      | 4.56 ± 0.43          | 0.10    |
| TMPG (mmHg)                              | 15.43 ± 6.86 | 15.28 ± 6.76     | 16.21 ± 7.4          | 0.64    |
| MVA (cm²)                                | 1.03 ± 0.20  | 1.02 ± 0.20      | 0.99 ± 0.21          | 0.55    |
| MR ≥ degree 1                           | 112 (60.2%)  | 91 (58.7%)       | 21 (67.7%)           | 0.38    |
| Wilkins score                            | 8.12 ± 1.21  | 8.02 ± 1.20      | 8.61 ± 1.14          | 0.021   |
| sPAP (mmHg)                              | 43.69 ± 12.9 | 42.38 ± 12.45    | 50.33 ± 13.28        | 0.003   |
| **Echocardiographic (Post-PTMC)**        |              |                  |                      |         |
| IMVA (cm²)                               | 2.03 ± 0.37  | 2.08 ± 0.35      | 1.76 ± 0.35          | < 0.001 |
| IMR: degree 2                            | 35 (18.8%)   | 23 (14.8%)       | 12 (38.7%)           | 0.002   |
| ITMPG (mmHg)                             | 5.49 ± 1.59  | 5.43 ± 1.56      | 5.75 ± 1.73          | 0.45    |

Values are mean ± SD or number (percentage in total). NYHA New York Heart Association, AF atrial fibrillation, EF ejection fraction, TMPG mean trans-mitral pressure gradient, MVA mitral valve area, MR mitral regurgitation, sPAP systolic pulmonary arterial pressure, IMVA immediate post-PTMC mitral valve area, IMR immediate post-PTMC mitral regurgitation, ITMPG immediate post-PTMC mean trans-mitral pressure gradient.
have mitral valve restenosis. Table 4 shows the follow-up echocardiographic and clinical findings in comparison with their respective peri-procedural values.

In order to identify predictive factors for the occurrence of mitral restenosis, the pre- and immediate post-PTMC characteristics of the patients with and without restenosis were compared with univariable logistic regression. This analysis detected only IMVA < 2 cm² as a significant predictor of restenosis \( (p < 0.001) \). In the next step the variables with \( p \leq 0.10 \) in the univariable analysis were entered into a multivariable logistic regression analysis. Again, IMVA < 2 cm² was the only significant variable \( (p = 0.001) \). The results of these analyses are shown in Table 5.

At last, ROC curves were recruited to obtain optimal IMVA cut-off points for predicting adverse cardiac events (Fig. 2) and also restenosis (Fig. 2); the calculated values were 1.925 cm² and 2.025 cm² respectively.

**Discussion**

The main finding of this study is the identification of heterogeneous factors of cardiac rhythm, valvular morphology and primary status of pulmonary arterial pressure as predictors of adverse cardiac events occurring in the long-term follow-up of patients who underwent PTMC for rheumatic MS. Furthermore, low IMVA (< 2 cm²) was found to be an independent predictive variable for both adverse cardiac events and restenosis.

To our knowledge this is the second study of the long-term outcomes of PTMC in Iran, and is one of the few such studies in the Middle East region [10, 13, 16]. According to epidemiologic studies worldwide, Iran is no longer an endemic area for rheumatic fever, in contrast to the situation in this country about 4 decades ago [2, 21]. However, we should not underestimate the existing burden of RHD and its major consequences such as MS, while a large group of sufferers are young adults under
have also reported at least one the first three factors to be a prognostic factor of PTMC results in the long-term [11–18, 22].

Aside from thromboembolic events, which can be a direct consequence of AF rhythm, our study is consistent with earlier works reporting that AF rhythm correlates positively with the incidence of cardiac events [13, 14, 16, 22]. Patients with AF in the present study were older and had higher NYHA functional classes and higher Wilkins scores than patients in sinus rhythm, in line with reports by other authors [16, 22]. Bouleti et al. suggested that although AF rhythm per se does not compromise mitral valve function, its presence is an indicator of more advanced stages of underlying rheumatic disease; thus the rate of clinical events will be higher in long-term [14]. A further implication is that impaired hemodynamics and subsequently more severe clinical symptoms in these groups of patients make re-intervention inevitable within a shorter time frame.

Considering Wilkins score, our results are also in line with multiple studies reporting that favorable morphological characteristics before the procedure can play a significant role in the long-term success of PTMC [10, 13, 14, 22]. Although other scoring systems have been introduced, based on estimating variables such as commissural calcium, commissural area or subvalvular characteristics, to date none has been as widely validated or accepted. The pathognomonic characteristic of rheumatic MS, and in avoiding severe MR – an

| Variables | Hazard ratio | 95% CI | p Value |
|-----------|--------------|--------|---------|
| Age       | 1.026        | 0.997–1.057 | 0.08 |
| Male Sex  | 0.458        | 0.138–1.501 | 0.19 |
| NYHA functional class > 3 | 1.249 | 0.575–2.713 | 0.57 |
| AF Rhythm | 3.459        | 1.699–7.042 | <0.001 |
| Antibiotic (penicillin) prophylaxis | 0.386 | 0.158–0.943 | 0.03 |
| E.F       | 0.942        | 0.674–1.105 | 0.11 |
| Left atrial diameter | 1.582 | 0.906–2.764 | 0.10 |
| TMPG      | 0.988        | 0.938–1.041 | 0.64 |
| MVA       | 0.601        | 0.111–3.236 | 0.55 |
| MR ≥ 1    | 1.397        | 0.658–2.968 | 0.38 |
| Wilkins score > 8 | 2.787 | 1.365–5.691 | 0.021 |
| sPAP      | 1.037        | 1.012–1.062 | 0.003 |
| IMVA      | 0.071        | 0.024–0.211 | <0.001 |
| IMVA ≥ 2 cm2 | 0.054 | 0.016–0.178 | <0.001 |
| IMRdegree 2 | 3.607 | 1.743–7.464 | 0.002 |
| ITMPG     | 1.083        | 0.879–1.334 | 0.45 |

CI confidence interval, NYHA New York Heart Association, AF atrial fibrillation, EF ejection fraction, TMPG mean trans-mitral pressure gradient, MVA mitral valve area, MR mitral regurgitation, sPAP systolic pulmonary arterial pressure, IMVA immediate post-PTMC mitral valve area, IMR immediate post-PTMC mitral regurgitation, ITMPG immediate post-PTMC mean trans-mitral pressure gradient
effect which becomes more likely when the valve is markedly deformed [1, 8, 25, 26].

An unexpected finding in the present study was the detection of higher pre-PTMC sPAP as an independent variable for predicting adverse cardiac events. Although a few studies have reported higher post-PTMC sPAP to be among the predictive factors, none indicated a similarly significant impact for pre-PTMC sPAP [24, 27]. Because of missing data regarding immediate post-procedural sPAP in some cases, we were unable to analyze the impact of this factor separately. However, some studies have shown that patients with high baseline pulmonary arterial pressure had poorer hemodynamic results in intermediate and late follow-up periods [28, 29]. Ozkan et al. suggested that because of the decrease in hemodynamic response to PTMC in patients with severe pulmonary hypertension in the long-term, it would be reasonable to perform PTMC at earlier stages [28]. In light of our parallel clinical finding, we also hypothesize that patients with high pulmonary arterial pressure, despite the documented substantial initial improvement after PTMC, may have surpassed the window of opportunity for this procedure, making it reasonable to opt directly for surgical management in some of these individuals.

The most significant predictive factor in the present study was IMVA, which proved to be clearly influential in predicting both cardiac events and restenosis. This finding is consistent with the results of earlier studies [13, 15, 18, 22], especially that by Song et al. [15]. In contrast with other studies, however, we obtained a slightly

![Table 5](image-url)

| Variables                  | Univariate OR (95% CI) | Univariate p value | Multivariate OR (95% CI) | Multivariate p Value |
|---------------------------|------------------------|--------------------|--------------------------|----------------------|
| Age                       | 1.013 (0.98–1.04)      | 0.39               |                          |                      |
| Male Sex                  | 0.972 (0.40–2.30)      | 0.94               |                          |                      |
| NYHA functional class > 2 | 1.144 (0.48–2.69)      | 0.75               |                          |                      |
| AF Rhythm                 | 2.008 (0.88–4.53)      | 0.09               | 1.977 (0.819–4.774)      | 0.15                 |
| Antibiotic (Penicillin)   | 0.732 (0.35–1.50)      | 0.39               |                          |                      |
| EF                        | 1.018 (0.936–1.108)    | 0.67               |                          |                      |
| Left atrial diameter      | 1.118 (0.62–1.98)      | 0.70               |                          |                      |
| TMPG                      | 1.036 (0.98–1.09)      | 0.17               |                          |                      |
| MVA                       | 1.09 (0.54–2.21)       | 0.78               |                          |                      |
| MR ≥ grade 1              | 1.306 (0.63–2.68)      | 0.46               |                          |                      |
| Wilkins score > 8         | 1.845 (0.86–3.93)      | 0.10               | 1.886 (0.833–4.268)      | 0.12                 |
| sPAP                      | 0.272 (0.04–1.61)      | 0.15               |                          |                      |
| ITMPG                     | 1.59 (0.93–1.444)      | 0.18               |                          |                      |
| IMVA ≥ 2cm2               | 0.231 (0.109–0.491)    | <0.001             | 0.240 (0.105–0.548)      | 0.001                |
| IMR: grade 2              | 2.14 (0.86–5.35)       | 0.10               | 1.097 (0.388–3.101)      | 0.86                 |

OR odds ratio, CI confidence interval, NYHA New York Heart Association, AF atrial fibrillation, EF ejection fraction, TMPG mean Trans-mitral pressure gradient, MVA mitral valve area, MR mitral regurgitation, sPAP systolic pulmonary arterial pressure, IMVA immediate post-PTMC mitral valve area, IMR immediate post-PTMC mitral regurgitation, ITMPG immediate post-PTMC mean trans-mitral pressure gradient.

**Fig. 2** ROC curves to evaluate the optimal IMVA cut-off point for predicting adverse cardiac events [1] and restenosis [2]. The area under curve is 0.784 and 0.717 figure.
higher cut-off value of 2.025 for predicting restenosis and 1.925 for predicting adverse cardiac events [15, 22]. The respective ROC curves to evaluate the diagnostic ability of IMVA are shown in Fig. 2. Song et al. suggested that IMVA is a significant indicator of the efficacy of the procedure, and at least for some more recent target groups of PTMC such as the patients with higher pre-PTMC MVA, a higher cut-off for success than the conventional \( \geq 1.5 \text{ cm}^2 \) value should be considered [15]. Tomai et al. also noted that better event-free outcomes in cases with higher IMVA reflect higher procedural quality in this group as well as a less advanced stage of rheumatic MS [22]. We also suggest, based on the present findings, that patients who have less than optimal IMVA results should be followed more closely during follow-up, as they are supposedly more prone to restenosis and more likely to be candidates for re-intervention.

To the best of our knowledge, the present study provides the first analysis of the possible impact of continuing secondary antibiotic prophylaxis on the mid-term outcome in patients who underwent PTMC. Because there was no valid system to monitor patients’ adherence to secondary penicillin prophylaxis at the participating centers, we assumed that patients who did not complete their post-intervention antibiotic regimen might have had a worse clinical outcome. This hypothesis was based on the fact that the repeated occurrence of subclinical rheumatic attacks can affect the post-intervention course of MS. However, this impact was not statistically significant in our results for the incidence of cardiac events or restenosis. In addition, we noted that except for one patient, all those who continued their antibiotic prophylaxis regimen were younger than 50 years of age. This was a logical finding given that based on guidelines for non-endemic area, we recommend that patients continue prophylaxis to around the age of 40. However, our analysis of the results in patients younger than 50 again showed that this impact was statistically nonsignificant. Nevertheless, we suggest that further research on this topic is needed, especially after the age of 70 [14]. Nunes et al. have also indicated that they had investigated a heterogeneous group of patients in regard of age and valvular morphology [24]. Therefore, we assume that the different age structure of our study population, in which only 7 patients were of the age of 70 or older have had an impact on our findings in this regard.

It is also noticeable, that in comparison to other similar studies, the rate of left ventricular dysfunction (EF < 50%) at the time of PTMC procedure was lower among our patients (9.13%). We consider the implemented criteria, such as excluding the patients with significant rheumatic involvement of aortic valve or the ones with high grade MR, and again the relatively younger mean age of our case as possible explanations for this difference.

**Limitations**

Our study had certain limitations. To obtain an acceptable number of patients, we had to collect data from multiple centers. However, by applying specific criteria and including only cases with immediate success and an initial event-free interval of 6 months, we tried to decrease the operator bias. In contrast, the protocols for echocardiographic imaging and the PTMC technique were completely the same at all centers.

The retrospective nature of this study is an added limitation. We lost a considerable proportion of our patients (15.4%) during follow-up. Additionally, the exact timing of the initiation of restenosis was unknown in some cases, thus we had to apply logistic regression to analyze the results for this factor. Furthermore, the available
information about the cause of death in 2 of our deceased patients was limited and mostly based on interviews with first-degree relatives. However, we were able to obtain and recheck the relevant documentation in 2 other cases.

**Conclusion**

After a relatively long period of time following PTMC, more than 80% of the patients remained event-free and more than 66% had an acceptable functional status based on NYHA class. The main independent predictors of adverse events were AF rhythm, initial Wilkins score > 8, high initial sPAP, and IMVA < 2 cm². Low IMVA was also the only variable predicting the incidence of restenosis. Although the effect of continuing secondary penicillin prophylaxis on the long-term outcome of PTMC was insignificant in this study, further research on this topic is recommended.

**Abbreviations**

PTMC: Percutaneous transvenous mitral commissurotomy; MVA: Mitral valve area; AF: Atrial fibrillation; HR: Hazard ratio; MS: Mitral stenosis; sPAP: Systolic pulmonary artery pressure; IMVA: Immediate post-PTMC mitral valve area; OR: Odds ratio; ARF: Acute rheumatic fever.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12872-021-02175-3.

**Acknowledgements**

We deeply appreciate the unlimited support of Deputy of Research in Baqiyatallah and Shiraz University of Medical Sciences as well as the staff of Kojuri Clinic and the Clinical Research Development Center of Baqiyatallah hospital throughout conducting this study. We are also grateful to Dr. Mehrdad Vosoughi and Ms. Karen Shashok (AuthorAID in the Eastern Mediterranean) for their great assist in statistical analysis of the provided data and linguistic editing of this article respectively.

**Authors’ contributions**

YD: Main author, Data-gathering, management of project, PTMC performance. MMF: Data gathering, echocardiography in follow up. RN: Student, Data gathering, Data analysis, MS writing, MS edition. MSG: Data gathering, PTMC performance. AM: Data gathering, echocardiography in follow up. JK: Corresponding author, Idea, PTMC performance, Writing article, Data analysis, submission, project management. All authors read and approved the final manuscript.

**Funding**

This article was conducted and funded by University of Baqiyatallah and Shiraz University of medical sciences.

**Availability of data and materials**

Free internet sharing of data are available and we do not use any personal data of our patient in this article.

**Declarations**

**Ethics approval and consent to participate**

This study was approved by ethics committee of Shiraz and Baqiyatallah University of medical sciences (ethics.research.ac.ir).

**Informed consent**

All participants were informed and filled the written consent.

**Consent for publication**

We authors of this study submit our manuscript to BMC cardiovascular disease and approve any data use of our article by the journal.

**Competing interests**

We authors declare that all of us have no competing interest.

**Impact on practice**

This is a rare report of late post PTMC result up to 12 years, which showed that AF rhythm, post PTMC MVA, Wilkins score and systolic pulmonary pressure were only predictors of long-term adverse cardiac events. Post PTMC MVA was also the predictor of MS restenosis. It seems that secondary antibiotic prophylaxis may play no role in prevention of restenosis in non-endemic areas.

**Author details**

1Cardiology Department, Clinical Research Center, Namazi Hospital, Shiraz University of Medical Sciences, Zand St., Cardiology Office, Shiraz, Iran.
2Atherosclerosis Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. 3Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

**Received: 15 March 2020 Accepted: 15 July 2021**

**Published online: 28 July 2021**

**References**

1. Marijon E, Mirabel M, Celerier D, Jouven X. Rheumatic heart disease. Lancet (London, England). 2012;379(9819):953–64.
2. Watkins DA, Johnson CO, Colquhoun SM, Karthikeyan G, Beaton A, Buikhman G, Forouzanfar MH, Longenecker CT, Mayosy BM, Mensah GA, Nascimento BR, Ribeiro ALP, Sable CA, Steer AC, Naghavi M, Mokdad AH, Murray CJL, Vos T, Carapets J, Roth GA. Global, regional, and national burden of rheumatic heart disease, 1990–2015. N Engl J Med. 2017;377(8):713–22.
3. Manjunath CN, Srinivas P, Ravindraranath KS, Dhanalakshmi C. Incidence and patterns of valvular heart disease in a tertiary care high-volume cardiac center: a single center experience. Indian Heart J. 2014;66(3):320–6.
4. Iung B, Vahanian A. Epidemiology of acquired valvular heart disease. Can J Cardiol. 2014;30(9):962–70.
5. Inoue K, Owaki T, Nakamura T, Kitamura F, Miyamoto N. Clinical application of transvenous mitral commissurotomography by a new balloon catheter. J Thorac Cardiovasc Surg. 1984;87(3):394–402.
6. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, Opara TP, Ruiz CE, Skubas NJ, Soriaja P, Sundt TM, Thomas JD. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(23):2440–92.
7. Ben Farhat M, Ayari M, Maatouk F, Bethbout F, Gamra H, Jarrar M, Tiss M, Hammami S, Thalabi R, Addad F. Percutaneous balloon valvuloplasty in a series of 528 patients and analysis of predictors. Catheter Cardiovasc Interv Off J Soc Cardiac Angiography. 2007;69(1):40–6.
8. Wilkins AE, Weyman AE, Abascal V, Block P, Palacios I, Gallardo N. Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation. Heart (British Cardiac Society). 1988;69(4):299–308.
9. Fawzy ME, Shokou M, Hassan W, Nambar V, Stefanoudos M, Canber CV. The impact of mitral valve morphology on the long-term outcome of mitral balloon valvuloplasty. Catheter Cardiovasc Interv Off J Soc Cardiac Angiography. 2001;48(1):40–6.
10. Iung B, Commer B, Ducimetier F, Porte JM, Nallet O, Michel PL, Acr J, Vahanian A. Functional results 5 years after successful percutaneous mitral commissurotomography in a series of 528 patients and analysis of predictive factors. J Am Coll Cardiol. 1996;27(2):407–14.
12. Saeki F, Ishiizaka Y, Tamura T. Long-term clinical and echocardiographic outcome in patients with mitral stenosis treated with percutaneous transvenous mitral commissurotomy. Jpn Circ J. 1999;63(8):597–604.

13. Fawzy ME, Shoukri M, Fadel B, Badr A, Al Ghamdi A, Carver C. Long-term (up to 18 years) clinical and echocardiographic results of mitral balloon valvuloplasty in 531 consecutive patients and predictors of outcome. Cardiology. 2009;113(3):213–21.

14. Bouleti C, Iung B, Laouénan C, Himbert D, Brochet E, Messika-Zeitoun D, Deltaint D, Garbarz E, Cormier B, Michel PL, Mentré F, Vahanian A. Late results of percutaneous mitral commissurotomy up to 20 years: development and validation of a risk score predicting late functional results from a series of 912 patients. Circulation. 2012;125(7):2119–27.

15. Song JK, Kim MJ, Yun SC, Choo SJ, Song JM, Song H, Kang DH, Chung CH, Park DW, Lee SW, Kim YH, Lee CW, Hong MK, Kim JJ, Lee JW, Park SW, Park SJ. Restenosis and adverse clinical events after successful percutaneous mitral valvuloplasty: immediate post-procedural mitral valve area as an important prognosticator. Eur Heart J. 2009;30(10):1254–62.

16. Afnanabadi N, Ghaffari S, Khezerlouy Aghdam N, Ahmadzade M, Kazemi B, Nasiri B, Sepahram A, Sadrabi B, Taban M, Aslanabadi A. Poor outcome following percutaneous balloon mitral valvotomy in patients with atrial fibrillation. J Cardiovasc Thorac Res. 2016;8(3):126–31.

17. Khan I, Shah B, Habeel Dar M, Khan A, Faisal Iftekhar M, Sami A. Clinical and echocardiographic follow-up after successful percutaneous transvenous mitral commissurotomy. Cureus. 2017;9(9):e1726.

18. Meneghelo Z, Maldonado M, Ferreira-Neto AN, Franca JID, Siqueira D, Esteves C, Sousa A, Sousa JE, Abizaid A. Very long term follow-up after transvenous mitral commissurotomy. Cureus. 2017;9(9):e1726.

19. Wang A, Krasuski RA, Warner JJ, Pieper K, Kisslo KB, Bashore TM. Harrison’s Cardiology. 2009;113(3):213–21.

20. Murthy Jayanthi Sriram SN, Venkata BJ, Sadagopan T, Ramamurthy MT. Current outcomes of percutaneous balloon mitral valvuloplasty for patients with mitral stenosis complicated by severe pulmonary hypertension develops? Efficacy of percutaneous mitral balloon valvuloplasty in patients with severe pulmonary hypertension: a subgroup analysis of our experience. Cardiol J. 2016;23(2):184–8.

21. Gharagozloo RA, Tomai F, Gaspardone A, Versaci F, Ghi A, Altamura L, De Luca L, Giofré G, Giofré P. Twenty year follow-up after successful percutaneous balloon mitral valvuloplasty in a large contemporary series of patients with mitral stenosis. Int J Cardiol. 2014;177(3):881–5.

22. Sutania N, Shaw TR, Prendergast B, Northridge D. Transoesophageal echocardiographic assessment of mitral valve commissural morphology predicts outcome after balloon mitral valvotomy. Heart. 2006;92(1):32–7.

23. Nunez MC, Tan TC, Elmirah S, do Lago R, Margery R, Cruz-Gonzalez I, Zheng H, Handschumacher MD, Inglessis I, Palacios IF, Weyman AE. The echo score revisited: Impact of incorporating commissural morphology and leaflet displacement to the prediction of outcome for patients undergoing percutaneous mitral valvuloplasty. Circulation. 2014;129(8):886–95.

24. Wunderlich NC, Dalvi B, Ho SY, Küç H, Siegel RJ. Rheumatic mitral valve stenosis: diagnosis and treatment options. Curr Cardiol Rep. 2019;21(3):14.

25. Radialh LR, Abascal VM, Moreno PR, Weyman AE, Levine IF. Echocardiography can predict the development of severe mitral regurgitation after percutaneous mitral valvuloplasty by the Inoue technique. Am J Cardiol. 1999;83(8):1210–3.

26. Chmielak Z, Kropotowski M, Demkow M, Konka M, Hoffman P, Kukula K, Kruk M, Witrkowsi A, Rzyfflo W. Percutaneous mitral balloon valvuloplasty beyond 65 years of age. Cardiol J. 2013;20(1):44–51.

27. Oktan H, Bozt T, Tiryakioglu SK, Ari H. Should we wait until severe pulmonary hypertension develops? Efficacy of percutaneous mitral balloon valvuloplasty in patients with severe pulmonary hypertension: a subgroup analysis of our experience. Cardiol J. 2016;23(2):184–8.

28. Maoqin S, Guoxiang H, Zhiyuan S, Luxiang C, Houyuan H, Liangyi S, Z, Guoqiang Z. The clinical and hemodynamic results of mitral balloon valvuloplasty for patients with mitral stenosis complicated by severe pulmonary hypertension. Eur J Int Med. 2005;16(6):413–8.

29. Gerber MA, Baltimore RS, Eaton CB, Gewitz M, Rowley AH, Shulman ST, Taubert KA. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation. 2009;119(11):1541–51.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.